Post hoc analyses of pooled data from two Phase III trials (TULIP-1/TULIP-2) including 726 SLE patients confirmed the effectiveness of anifrolumab (300 mg monthly), especially for patients with high IFN gene signatures (92). Here, IFNA1 is linked to systemic lupus erythematosus.